Experimental models of Huntington's disease

被引:9
|
作者
Garcia-Ramos, R.
del Val-Fernandez, J.
Catalan-Alonso, M. J.
Barcia-Albacar, J. A.
Matias-Guiu, J.
机构
[1] Hosp Clin San Carlos, Unidad Trastornos Movimiento, E-28040 Madrid, Spain
[2] Hosp Clin San Carlos, Serv Neurocirugia, E-28040 Madrid, Spain
[3] Hosp Clin San Carlos, Inst Neurociencias, E-28040 Madrid, Spain
关键词
3-nitropropionic acid; cellular models; excitotoxic models; Huntington's disease; quinolinic acid; Transgenic mice;
D O I
10.33588/rn.4507.2007238
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Huntington's disease (HD) is an autosomal dominant hereditary disease caused by triplet repetition in exon I of the huntingtin protein located in chromosome 4. Medium spiny neurons in the striatum are selectively affected. Clinical manifestations include progressive behavioural, motor and cognitive disorders. There is no treatment available today capable of modifying the natural course of the disease. A great amount of research work is being carried out, much of which involves animal models of the disease. Development. We reviewed the articles published in PubMed on basic research into HD and analysed the most frequently used models. Transgenic mouse models, excitotoxic models, transgenic fly models and cell cultures are all used in studies into HD. The advantages and disadvantages of each of them are highlighted. Conclusion. The contribution made by each model of HD must be known in order to draw up a correct design in experimental studies of the disease. [REV NEUROL 2007; 45: 437-41]
引用
收藏
页码:437 / 441
页数:5
相关论文
共 50 条
  • [1] Citicoline is not protective in experimental models of Huntington's disease
    Mievis, Stephane
    Levivier, Marc
    Vassart, Gilbert
    Brotchi, Jacques
    Ledent, Catherine
    Blum, David
    NEUROBIOLOGY OF AGING, 2007, 28 (12) : 1944 - 1946
  • [2] Experimental therapeutics in mouse models of Huntington's disease
    Hockly, E
    Lupton, MK
    Sunshine, S
    Tse, J
    Woodman, B
    Bates, GP
    Revington, AP
    Lowden, PAS
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [3] Experimental therapeutics in transgenic mouse models of Huntington's disease
    Beal, MF
    Ferrante, RJ
    NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) : 373 - 384
  • [4] Huntington’s disease and mitochondrial alterations: emphasis on experimental models
    Verónica Pérez-De la Cruz
    Paul Carrillo-Mora
    Abel Santamaría
    Journal of Bioenergetics and Biomembranes, 2010, 42 : 207 - 215
  • [5] Huntington's disease and mitochondrial alterations: emphasis on experimental models
    Perez-De la Cruz, Veronica
    Carrillo-Mora, Paul
    Santamaria, Abel
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2010, 42 (03) : 207 - 215
  • [6] Experimental therapeutics in transgenic mouse models of Huntington's disease
    M. Flint Beal
    Robert J. Ferrante
    Nature Reviews Neuroscience, 2004, 5 : 373 - 384
  • [7] Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
    Brett, Ana C.
    Rosenstock, Tatiana R.
    Rego, A. Cristina
    CURRENT DRUG TARGETS, 2014, 15 (03) : 313 - 334
  • [8] Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
    Bates, GP
    Hockly, E
    CURRENT OPINION IN NEUROLOGY, 2003, 16 (04) : 465 - 470
  • [9] Fly models of Huntington's disease
    Marsh, JL
    Pallos, J
    Thompson, LM
    HUMAN MOLECULAR GENETICS, 2003, 12 : R187 - R193
  • [10] Mouse models of Huntington's disease
    Menalled, LB
    Chesselet, MF
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (01) : 32 - 39